Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

565 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Deep gray matter volume loss drives disability worsening in multiple sclerosis.
Eshaghi A, Prados F, Brownlee WJ, Altmann DR, Tur C, Cardoso MJ, De Angelis F, van de Pavert SH, Cawley N, De Stefano N, Stromillo ML, Battaglini M, Ruggieri S, Gasperini C, Filippi M, Rocca MA, Rovira A, Sastre-Garriga J, Vrenken H, Leurs CE, Killestein J, Pirpamer L, Enzinger C, Ourselin S, Wheeler-Kingshott CAMG, Chard D, Thompson AJ, Alexander DC, Barkhof F, Ciccarelli O; MAGNIMS study group. Eshaghi A, et al. Among authors: ruggieri s. Ann Neurol. 2018 Feb;83(2):210-222. doi: 10.1002/ana.25145. Epub 2018 Feb 6. Ann Neurol. 2018. PMID: 29331092 Free PMC article.
New oral drugs for multiple sclerosis.
Gasperini C, Ruggieri S. Gasperini C, et al. Among authors: ruggieri s. Neurol Sci. 2009 Oct;30 Suppl 2:S179-83. doi: 10.1007/s10072-009-0146-3. Neurol Sci. 2009. PMID: 19882371 Review.
Pronounced focal and diffuse brain damage predicts short-term disease evolution in patients with clinically isolated syndrome suggestive of multiple sclerosis.
Sbardella E, Tomassini V, Stromillo ML, Filippini N, Battaglini M, Ruggieri S, Ausili Cefaro L, Raz E, Gasperini C, Sormani MP, Pantano P, Pozzilli C, De Stefano N. Sbardella E, et al. Among authors: ruggieri s. Mult Scler. 2011 Dec;17(12):1432-40. doi: 10.1177/1352458511414602. Epub 2011 Jul 5. Mult Scler. 2011. PMID: 21729978
Changes in magnetic resonance imaging disease measures over 3 years in mildly disabled patients with relapsing-remitting multiple sclerosis receiving interferon β-1a in the COGnitive Impairment in MUltiple Sclerosis (COGIMUS) study.
Bastianello S, Giugni E, Amato MP, Tola MR, Trojano M, Galletti S, Luccichenti G, Quarantelli M, Picconi O, Patti F; COGIMUS study group. Bastianello S, et al. BMC Neurol. 2011 Oct 14;11:125. doi: 10.1186/1471-2377-11-125. BMC Neurol. 2011. PMID: 21999142 Free PMC article. Clinical Trial.
Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone.
Martinelli V, Cocco E, Capra R, Salemi G, Gallo P, Capobianco M, Pesci I, Ghezzi A, Pozzilli C, Lugaresi A, Bellantonio P, Amato MP, Grimaldi LM, Trojano M, Mancardi GL, Bergamaschi R, Gasperini C, Rodegher M, Straffi L, Ponzio M, Comi G; Italian Mitoxantrone Group. Martinelli V, et al. Neurology. 2011 Nov 22;77(21):1887-95. doi: 10.1212/WNL.0b013e318238ee00. Epub 2011 Nov 9. Neurology. 2011. PMID: 22076543
Emerging oral drugs for relapsing-remitting multiple sclerosis.
Gasperini C, Ruggieri S. Gasperini C, et al. Among authors: ruggieri s. Expert Opin Emerg Drugs. 2011 Dec;16(4):697-712. doi: 10.1517/14728214.2011.642861. Epub 2011 Dec 7. Expert Opin Emerg Drugs. 2011. PMID: 22148963 Review.
565 results